Press Release: STIVARGA : Bayer's Stivarga® (regorafenib) becomes first compound used in clinical trial platform to investigate new therapies for brain cancer

WHIPPANY, N.J., June 19, 2019 /PRNewswire/ -- Bayer announced today that the Stivarga® (regorafenib) arm of the platform trial GBM AGILE (Glioblastoma Adaptive Global Innovative Learning Environment) has opened enrollment for patients with newly diagnosed and recurrent glioblastoma, the...